HRP20191477T1 - Farmaceutski sastav s-ketamin hidroklorida - Google Patents
Farmaceutski sastav s-ketamin hidroklorida Download PDFInfo
- Publication number
- HRP20191477T1 HRP20191477T1 HRP20191477T HRP20191477T1 HR P20191477 T1 HRP20191477 T1 HR P20191477T1 HR P20191477 T HRP20191477 T HR P20191477T HR P20191477 T1 HRP20191477 T1 HR P20191477T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- depression
- composition according
- present
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 21
- 229960004184 ketamine hydrochloride Drugs 0.000 title claims 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 9
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 208000020401 Depressive disease Diseases 0.000 claims 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 3
- 229960003299 ketamine Drugs 0.000 claims 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 201000003104 endogenous depression Diseases 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Farmaceutski sastav koji obuhvaća S-ketamin hidroklorid i vodu; pri čemu farmaceutski sastav ne obuhvaća antimikrobni konzervans;
pri čemu S-ketamin hidroklorid se nalazi u koncentraciji od najmanje ekv. 120 mg/mL, na temelju ukupnog volumena sastava.
2. Farmaceutski sastav prema zahtjevu 1, koji
(i) dodatno sadrži pufer; i/ili
(ii) ima pH vrijednost u opsegu od 4.0 do 6.5.
3. Farmaceutski sastav prema zahtjevu 1, pri čemu S-ketamin hidroklorid se nalazi u koncentraciji u opsegu od ekv. 125 mg/mL do ekv. 150 mg/mL, na temelju ukupnog volumena sastava; ili pri čemu S-ketamin hidroklorid se nalazi u koncentraciji u opsegu od 126 mg / mL do 162 mg/mL, na temelju ukupnog volumena sastava.
4. Farmaceutski sastav prema zahtjevu 1, pri čemu je farmaceutski sastav formuliran za nazalnu primjenu.
5. Farmaceutski sastav prema zahtjevu 1, pri čemu farmaceutski sastav dalje sadrži pufer.
6. Farmaceutski sastav prema zahtjevu 5, pri čemu je pufer 1N NaOH.
7. Farmaceutski sastav prema zahtjevu 5, pri čemu se pufer nalazi u količini koja je dovoljna da se podesi pH farmaceutskog sastava do pH u opsegu od pH 3.5 do pH 6.5; ili pri čemu se pufer nalazi u količini koja je dovoljna da se podesi pH sastava do pH u opsegu od pH 4.5 do pH 5.5.
8. Farmaceutski sastav prema zahtjevu 1, pri čemu farmaceutski sastav pokazuje vrijeme trajanja pod ubrzanim uvjetima skladištenja od najmanje 3 mjeseca.
9. Farmaceutski oblik doziranja koji obuhvaća farmaceutski sastav prema bilo kojem od zahtjeva 1-8.
10. Oblik doziranja prema zahtjevu 9, koji je prilagođen za nazalnu primjenu.
11. Farmaceutski sastav prema zahtjevu 1 ili farmaceutski oblik doziranja prema zahtjevu 9 za upotrebu u liječenju depresije.
12. Farmaceutski sastav ili farmaceutski oblik doziranja za upotrebu prema zahtjevu 11, pri čemu je depresija odabrana iz grupe koja obuhvaća veliki depresivni poremećaj, unipolarnu depresiju, liječenje refraktorne depresije, rezistentnu depresiju, anksioznu depresiju i bipolarnu depresiju.
13. Farmaceutski sastav ili farmaceutski oblik doziranja za upotrebu prema zahtjevu 11, pri čemu je depresija odabrana iz grupe koja obuhvaća rezistentnu depresiju ili liječenje refraktorne depresije.
14. Farmaceutski sastav prema zahtjevu 1, koji obuhvaća S-ketamin HCl; limunsku kiselinu; dinatrijev edetat; natrijev hidroksid; i vodu.
15. Farmaceutski sastav prema zahtjevu 1, koji obuhvaća
(a) S-ketamin HCl; pri čemu se S-Ketamin HCl nalazi u količini od oko 161.4 mg/ml;
(b) limunsku kiselinu 1 vodu; pri čemu se limunska kiselina nalazi u količini od oko 1.5 mg/ml;
(c) dinatrijev edetat; pri čemu se dinatrijev edetat nalazi u količini od oko 0.12 mg/ml;
(d) natrijev hidroksid; pri čemu se natrijev hidroksid nalazi u količini koja je dovoljna da se podesi pH farmaceutskog sastava do pH od oko 4.5; i
(e) vodu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791505P | 2013-03-15 | 2013-03-15 | |
| EP14719471.6A EP2968221B1 (en) | 2013-03-15 | 2014-03-14 | Pharmaceutical composition of s-ketamine hydrochloride |
| PCT/US2014/027074 WO2014143646A1 (en) | 2013-03-15 | 2014-03-14 | Pharmaceutical composition of s-ketamine hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191477T1 true HRP20191477T1 (hr) | 2019-12-13 |
Family
ID=50549465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191477 HRP20191477T1 (hr) | 2013-03-15 | 2019-08-14 | Farmaceutski sastav s-ketamin hidroklorida |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20140275276A1 (hr) |
| EP (3) | EP2968221B1 (hr) |
| KR (3) | KR20230156807A (hr) |
| CN (3) | CN111297803A (hr) |
| AU (6) | AU2014228324B2 (hr) |
| CL (1) | CL2015002733A1 (hr) |
| CR (1) | CR20150480A (hr) |
| CY (1) | CY1121928T1 (hr) |
| DK (1) | DK2968221T3 (hr) |
| ES (1) | ES2745024T3 (hr) |
| HR (1) | HRP20191477T1 (hr) |
| HU (1) | HUE045982T2 (hr) |
| LT (1) | LT2968221T (hr) |
| ME (1) | ME03465B (hr) |
| MX (1) | MX2015012342A (hr) |
| MY (1) | MY191332A (hr) |
| NZ (1) | NZ712270A (hr) |
| PE (2) | PE20191796A1 (hr) |
| PH (1) | PH12015501957A1 (hr) |
| PL (1) | PL2968221T3 (hr) |
| PT (1) | PT2968221T (hr) |
| RS (1) | RS59130B1 (hr) |
| SG (3) | SG11201507358VA (hr) |
| SI (1) | SI2968221T1 (hr) |
| WO (1) | WO2014143646A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015037248A1 (en) | 2013-09-13 | 2015-03-19 | National University Corporation Chiba University | Application of r-ketamine and salt thereof as pharmaceuticals |
| CA2936809A1 (en) | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| CN106562952B (zh) * | 2015-10-09 | 2020-06-09 | 江阴安博生物医药有限公司 | ***在治疗重性抑郁障碍中的应用 |
| WO2018191482A2 (en) * | 2017-04-13 | 2018-10-18 | Ovid Therapeutics Inc. | Methods of treating developmental encephalopathies |
| EP3505157B1 (en) | 2017-12-29 | 2021-12-08 | Celon Pharma S.A. | Dry powder ketamine composition for pulmonary administration in treatment-resistant depression |
| JPWO2019160057A1 (ja) | 2018-02-15 | 2021-02-04 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| AU2019262197A1 (en) | 2018-05-04 | 2020-11-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| EP3628313A1 (en) | 2018-09-28 | 2020-04-01 | Celon Pharma S.A. | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| CA3140035A1 (en) | 2019-05-31 | 2020-12-03 | Celon Pharma S.A. | An inhaler for electronically supervised parenteral administration of a pharmaceutical composition |
| JP2022542746A (ja) | 2019-05-31 | 2022-10-07 | セロン ファーマ エス．アー． | 医薬組成物の電子的に監督された投与 |
| JP2022548233A (ja) * | 2019-09-13 | 2022-11-17 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | エスケタミンの鼻腔内投与 |
| US11160799B2 (en) * | 2019-10-22 | 2021-11-02 | Cessatech A/S | Pediatric combination |
| AR120816A1 (es) * | 2019-12-20 | 2022-03-23 | Alar Pharmaceuticals Inc | Formulaciones inyectables de larga duración de sales de pamoato de ketamina |
| CN114903840A (zh) * | 2021-02-08 | 2022-08-16 | 四川普锐特药业有限公司 | 一种治疗抑郁症的低剂量r-***经鼻药物 |
| CN113813250B (zh) * | 2021-07-21 | 2023-05-05 | 广州新济药业科技有限公司 | 含***的药物组合物及其制备方法和应用 |
| CN116942647A (zh) * | 2022-04-26 | 2023-10-27 | 宜昌人福药业有限责任公司 | 艾司***液体制剂及其用途 |
| US12005035B1 (en) * | 2023-08-14 | 2024-06-11 | Daniel C. Javitt | Compositions and methods for treatment of chronic pain and depression |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
| US6572849B2 (en) * | 2000-09-20 | 2003-06-03 | Lee Shahinian, Jr. | Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications |
| US6881731B1 (en) | 2000-10-23 | 2005-04-19 | Shanbrom Technologies, Llc | Enhancers for microbiological disinfection |
| US8785500B2 (en) * | 2006-03-22 | 2014-07-22 | Icahn School Of Medicine At Mount Sinai | Intranasal administration of ketamine to treat depression |
| DE102007009888A1 (de) * | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| JP6722453B2 (ja) * | 2012-08-23 | 2020-07-15 | スチュアート エル ウェグ | 抗不安薬組成物、製剤および使用方法 |
-
2014
- 2014-03-14 ES ES14719471T patent/ES2745024T3/es active Active
- 2014-03-14 CN CN201911264371.XA patent/CN111297803A/zh active Pending
- 2014-03-14 RS RS20191043A patent/RS59130B1/sr unknown
- 2014-03-14 SG SG11201507358VA patent/SG11201507358VA/en unknown
- 2014-03-14 CN CN201480015763.1A patent/CN105073103A/zh active Pending
- 2014-03-14 EP EP14719471.6A patent/EP2968221B1/en not_active Revoked
- 2014-03-14 PE PE2019002294A patent/PE20191796A1/es unknown
- 2014-03-14 US US14/212,565 patent/US20140275276A1/en not_active Abandoned
- 2014-03-14 EP EP19151099.9A patent/EP3498268A1/en not_active Withdrawn
- 2014-03-14 WO PCT/US2014/027074 patent/WO2014143646A1/en active Application Filing
- 2014-03-14 PE PE2015001997A patent/PE20160052A1/es active IP Right Grant
- 2014-03-14 SG SG10201912735TA patent/SG10201912735TA/en unknown
- 2014-03-14 ME MEP-2019-229A patent/ME03465B/me unknown
- 2014-03-14 NZ NZ712270A patent/NZ712270A/en unknown
- 2014-03-14 DK DK14719471.6T patent/DK2968221T3/da active
- 2014-03-14 LT LTEP14719471.6T patent/LT2968221T/lt unknown
- 2014-03-14 AU AU2014228324A patent/AU2014228324B2/en active Active
- 2014-03-14 MX MX2015012342A patent/MX2015012342A/es active IP Right Grant
- 2014-03-14 US US14/212,988 patent/US20140275277A1/en not_active Abandoned
- 2014-03-14 SI SI201431255T patent/SI2968221T1/sl unknown
- 2014-03-14 PT PT14719471T patent/PT2968221T/pt unknown
- 2014-03-14 EP EP23194654.2A patent/EP4309735A3/en active Pending
- 2014-03-14 HU HUE14719471A patent/HUE045982T2/hu unknown
- 2014-03-14 CN CN202310142376.5A patent/CN116251084A/zh active Pending
- 2014-03-14 MY MYPI2015703106A patent/MY191332A/en unknown
- 2014-03-14 KR KR1020237037938A patent/KR20230156807A/ko not_active Application Discontinuation
- 2014-03-14 PL PL14719471T patent/PL2968221T3/pl unknown
- 2014-03-14 KR KR1020217006306A patent/KR20210028278A/ko not_active IP Right Cessation
- 2014-03-14 KR KR1020157029474A patent/KR20150129023A/ko active Application Filing
- 2014-03-14 SG SG10201802106TA patent/SG10201802106TA/en unknown
-
2015
- 2015-09-04 PH PH12015501957A patent/PH12015501957A1/en unknown
- 2015-09-11 CR CR20150480A patent/CR20150480A/es unknown
- 2015-09-15 CL CL2015002733A patent/CL2015002733A1/es unknown
-
2019
- 2019-02-01 AU AU2019200702A patent/AU2019200702B2/en active Active
- 2019-02-01 AU AU2019200705A patent/AU2019200705B2/en active Active
- 2019-02-01 AU AU2019200696A patent/AU2019200696B2/en active Active
- 2019-08-14 HR HRP20191477 patent/HRP20191477T1/hr unknown
- 2019-08-23 CY CY20191100904T patent/CY1121928T1/el unknown
-
2021
- 2021-01-07 AU AU2021200072A patent/AU2021200072A1/en not_active Abandoned
-
2023
- 2023-02-20 AU AU2023200976A patent/AU2023200976A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191477T1 (hr) | Farmaceutski sastav s-ketamin hidroklorida | |
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| BR112018000592A2 (pt) | composição de desbloqueio de nariz congestionado tendo atividade antiviral | |
| BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
| JP2015527402A5 (hr) | ||
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| JP2015534562A5 (hr) | ||
| BR112015022972A2 (pt) | composição farmacêutica de cloridrato de s-cetamina | |
| HRP20171092T1 (hr) | Stabilna tekuća formulacija amg 416 (velkalcetid) | |
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| SI2889033T1 (en) | Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| RS54711B1 (en) | PARENTERAL TAPENTADOL ADMINISTRATION | |
| JP2018532806A5 (hr) | ||
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| RS54632B1 (en) | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING NITIZINON | |
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| MX2019003698A (es) | Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada. | |
| HRP20201598T1 (hr) | Pripravci | |
| HRP20211308T1 (hr) | Veterinarski postupak za izazivanje emeze | |
| EA201992382A2 (ru) | Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения | |
| BR112015025058A2 (pt) | composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma |